Drug profile · INN
rosuvastatin calcium
ROSUVASTATIN CALCIUM
rosuvastatin calcium (ROSUVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — rosuvastatin calcium
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 2
- Programs
- 3
- Data quality
- 0.89
Quick answer
rosuvastatin calcium (ROSUVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
HMG-CoA reductase inhibitor
Primary target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is rosuvastatin calcium?
rosuvastatin calcium (ROSUVASTATIN CALCIUM) is a hmg-coa reductase inhibitor. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for rosuvastatin calcium?
ROSUVASTATIN CALCIUM is a marketed brand name for rosuvastatin calcium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of rosuvastatin calcium?
rosuvastatin calcium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.